Ruben J. Colman

1.2k total citations · 1 hit paper
35 papers, 842 citations indexed

About

Ruben J. Colman is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Ruben J. Colman has authored 35 papers receiving a total of 842 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Genetics, 21 papers in Epidemiology and 11 papers in Immunology. Recurrent topics in Ruben J. Colman's work include Inflammatory Bowel Disease (27 papers), Microscopic Colitis (19 papers) and Biosimilars and Bioanalytical Methods (7 papers). Ruben J. Colman is often cited by papers focused on Inflammatory Bowel Disease (27 papers), Microscopic Colitis (19 papers) and Biosimilars and Bioanalytical Methods (7 papers). Ruben J. Colman collaborates with scholars based in United States, Netherlands and Italy. Ruben J. Colman's co-authors include David T. Rubin, Russell D. Cohen, David T. Rubin, Phillip Minar, Michael J. Rosen, Britt Christensen, Andrés Yarur, Christopher R. Weber, Dejan Micić and Tomoyuki Mizuno and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and The American Journal of Gastroenterology.

In The Last Decade

Ruben J. Colman

34 papers receiving 813 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fecal microbiota transplantation as therapy for inflammatory bowel disease: A systematic review and meta-analysis

2014 356 citations Ruben J. Colman, David T. Rubin Journal of Crohn s and Colitis profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ruben J. Colman United States	15	461	390	276	230	172	35	842
Anna Zholudev United States	7	689 1.5×	467 1.2×	225 0.8×	112 0.5×	282 1.6×	7	1.2k
Bobby Lo Denmark	16	408 0.9×	347 0.9×	223 0.8×	187 0.8×	232 1.3×	39	819
Sudheer K. Vuyyuru India	14	391 0.8×	289 0.7×	147 0.5×	134 0.6×	238 1.4×	84	759
Sieglinde Angelberger Austria	13	401 0.9×	382 1.0×	243 0.9×	283 1.2×	291 1.7×	32	839
Gøri Perminow Norway	15	432 0.9×	316 0.8×	188 0.7×	70 0.3×	239 1.4×	26	685
Jeffrey Berinstein United States	12	321 0.7×	284 0.7×	109 0.4×	140 0.6×	154 0.9×	60	611
Michal Kori Israel	14	496 1.1×	366 0.9×	200 0.7×	99 0.4×	698 4.1×	46	1.1k
Els Van de Vijver Belgium	14	461 1.0×	361 0.9×	127 0.5×	48 0.2×	292 1.7×	27	930
Garrett Lawlor United States	15	436 0.9×	481 1.2×	114 0.4×	139 0.6×	207 1.2×	48	908
Federica Nuti Italy	18	626 1.4×	436 1.1×	135 0.5×	69 0.3×	353 2.1×	41	997

Countries citing papers authored by Ruben J. Colman

Since Specialization

Citations

This map shows the geographic impact of Ruben J. Colman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruben J. Colman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruben J. Colman more than expected).

Fields of papers citing papers by Ruben J. Colman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruben J. Colman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruben J. Colman. The network helps show where Ruben J. Colman may publish in the future.

Co-authorship network of co-authors of Ruben J. Colman

This figure shows the co-authorship network connecting the top 25 collaborators of Ruben J. Colman. A scholar is included among the top collaborators of Ruben J. Colman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruben J. Colman. Ruben J. Colman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goyal, Alka, Rachel Bensen, Dorsey Bass, et al.. (2025). Intensified Upadacitinib Dosing for Adolescent Patients with Acute Severe Ulcerative Colitis. Children. 12(4). 401–401.

Colman, Ruben J., Virginia Solitano, John K MacDonald, et al.. (2024). Operating Properties of Disease Activity Indices in Pediatric Inflammatory Bowel Disease: A Systematic Review. Inflammatory Bowel Diseases. 31(1). 220–245. 1 indexed citations

Minar, Phillip, Ruben J. Colman, Nanhua Zhang, Tomoyuki Mizuno, & Alexander A. Vinks. (2024). Precise infliximab exposure and pharmacodynamic control to achieve deep remission in paediatric Crohn’s disease (REMODEL-CD): study protocol for a multicentre, open-label, pragmatic clinical trial in the USA. BMJ Open. 14(3). e077193–e077193. 4 indexed citations

Colman, Ruben J., Ron A. A. Mathôt, Johan Van Limbergen, et al.. (2023). Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn’s Disease Exhibit Similar Pharmacokinetics. Inflammatory Bowel Diseases. 30(10). 1678–1685. 2 indexed citations

Solitano, Virginia, Antonio Facciorusso, Dermot McGovern, et al.. (2023). HLA-DQA1∗05 Genotype and Immunogenicity to Tumor Necrosis Factor-α Antagonists: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology. 21(12). 3019–3029.e5. 28 indexed citations

Colman, Ruben J., Tomoyuki Mizuno, Keizo Fukushima, et al.. (2022). Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance. Alimentary Pharmacology & Therapeutics. 57(5). 524–539. 12 indexed citations

Colman, Ruben J., Tomoyuki Mizuno, Joshua D. Noe, et al.. (2022). REAL-WORLD VEDOLIZUMAB PHARMACOKINETIC STUDY IN CHILDREN IDENTIFIES TWO NOVEL BIOMARKERS OF DRUG CLEARANCE. Inflammatory Bowel Diseases. 28(Supplement_1). S100–S100. 1 indexed citations

Colman, Ruben J., Tomoyuki Mizuno, Jeffrey S. Hyams, et al.. (2021). Antibodies‐to‐infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn’s disease. Alimentary Pharmacology & Therapeutics. 55(5). 593–603. 23 indexed citations

Colman, Ruben J., Yi‐Ting Tsai, Kimberly Jackson, et al.. (2020). Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn’s Disease. Inflammatory Bowel Diseases. 27(7). 1045–1051. 16 indexed citations

10.

Christensen, Britt, Peter R. Gibson, Dejan Micić, et al.. (2018). Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology. 17(3). 486–493. 59 indexed citations

11.

Cleveland, Noa Krugliak, Jacob E. Ollech, Ruben J. Colman, et al.. (2018). Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia. Clinical Gastroenterology and Hepatology. 17(1). 205–206. 18 indexed citations

12.

Christensen, Britt, Ruben J. Colman, Dejan Micić, et al.. (2018). Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflammatory Bowel Diseases. 24(4). 849–860. 35 indexed citations

13.

Colman, Ruben J. & David T. Rubin. (2016). Histological inflammation increases the risk of colorectal neoplasia in ulcerative colitis: a systematic review. Intestinal Research. 14(3). 202–202. 46 indexed citations

14.

Christensen, Britt, Ruben J. Colman, Andrés Yarur, et al.. (2015). Tu1351 Crohn's Disease Patients Currently or Previously on Natalizumab Can Be Safely and Effectively Switched to Vedolizumab. Gastroenterology. 148(4). S–866. 1 indexed citations

15.

Hirsch, Ayal, Ruben J. Colman, Gabriel Lang, & David T. Rubin. (2015). Successful Treatment of Ulcerative Colitis With Vedolizumab in a Patient With an Infliximab-Associated Psoriasiform Rash. ACG Case Reports Journal. 2(1). 236–238. 6 indexed citations

16.

Cleveland, Noa Krugliak, Ruben J. Colman, Ayal Hirsch, et al.. (2015). Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. Inflammatory Bowel Diseases. 22(3). 631–637. 20 indexed citations

17.

Christensen, Britt, David T. Rubin, Ruben J. Colman, et al.. (2015). Endoscopic and Histologic Response and Remission in Inflammatory Bowel Disease Patients Initiating Vedolizumab. The American Journal of Gastroenterology. 110. S783–S784. 1 indexed citations

18.

Colman, Ruben J. & David T. Rubin. (2015). Optimal Doses of Methotrexate Combined with Anti-TNF Therapy to Maintain Clinical Remission in Inflammatory Bowel Disease. Journal of Crohn s and Colitis. 9(4). 312–317. 30 indexed citations

19.

Colman, Ruben J. & David T. Rubin. (2014). Fecal microbiota transplantation as therapy for inflammatory bowel disease: A systematic review and meta-analysis. Journal of Crohn s and Colitis. 8(12). 1569–1581. 356 indexed citations breakdown →

20.

Kazemi, H. & Ruben J. Colman. (1969). EACA and Intravascular Coagulation. New England Journal of Medicine. 281(22). 1247–1247. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact